.png)
Lighthouse
Three CMO Need-to-Knows about Clinical Trial Awareness
A CMO is responsible for compound development success, so building awareness proactively and compliantly is critical for clinical trials.
top of page
Lighthouse
Blood-based Biomarkers in Cancer
Liquid biopsy for cancer is non-invasive and easily repeated, permitting molecular profiling and many other purposes with strong accuracy.
Lighthouse
Clinical Trial Problems in the United Kingdom
Clinical trials held in the UK have seen patient enrollment and trial numbers drop. Flexibility & creativity are needed to overcome issues.
Lighthouse
Blood-based Biomarkers in Alzheimer’s Disease
Blood-based biomarkers (BBMs) hold promise for a fast, convenient, and simple means to accurately diagnose Alzheimer's Disease.
Lighthouse
How Does Awareness of Biomarkers Compare to Prevalence?
We compared awareness in oncologists of selected biomarkers to the prevalence of actionable oncogenic mutations across cancers.
Lighthouse
RAS Biomarker Trending and Awareness in Oncologists
We examined RAS/KRAS trending and awareness for oncologists; results track strongly with the history of scientific KRAS advancements.
Lighthouse
NTRK Trending and Awareness in Community Oncologists
We analyzed trending and awareness patterns of NTRK and NTRK-targeting compounds in academic and community oncologists.
Lighthouse
What is an Awareness Algorithm?
Awareness of new and emerging cancer biomarkers and compounds is vital so HCPs will test for and treat molecular oncogenic drivers.
bottom of page